TABLE 4

Safety summaries in the SAD study

Data are given as n (%).

	All		Placebo			BMS-932481
	Placebo	Treated	NHY	Elderly	CSF	10 mg	30 mg	100 mg	300 mg P	300 mg P2	300 mg P3	600 mg	900 mg	1200 mg	900 mg El	900 mg C
Participants, n	22	61	14	3	5	6	6	6	6	6	6	6	6	6	6	6
Deaths	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SAEs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Discontinuation due to AEs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
AEs	7 (31.8)	17 (27.9)	24 (28.6)	1 (33.3)	2 (40.0)	3 (50.0)	2 (33.3)	1 (16.7)	0	0	1 (16.7)	0	3 (50.0)	0	0	7 (70.0)
Drug-related AEs	1 (4.5)	2 (3.3)	1 (7.1)	0	0	0	0	0	0	0	0	0	1 (16.7)	0	0	1 (10.0)

E1, Elderly; NHY, Normal healthy young; P1, P2, P3, cross-over phase 1, 2 or 3.